United Services Automobile Association decreased its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 4.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 56,638 shares of the medical research company’s stock after selling 2,590 shares during the period. United Services Automobile Association’s holdings in Iqvia were worth $5,654,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Iqvia by 5.7% during the second quarter. BlackRock Inc. now owns 10,170,048 shares of the medical research company’s stock worth $1,015,173,000 after buying an additional 546,878 shares during the period. Northern Trust Corp lifted its position in Iqvia by 7.0% in the second quarter. Northern Trust Corp now owns 1,877,470 shares of the medical research company’s stock valued at $187,408,000 after purchasing an additional 122,260 shares during the period. Morgan Stanley lifted its position in Iqvia by 0.3% in the second quarter. Morgan Stanley now owns 1,214,945 shares of the medical research company’s stock valued at $121,278,000 after purchasing an additional 4,093 shares during the period. Bank of New York Mellon Corp lifted its position in Iqvia by 5.9% in the second quarter. Bank of New York Mellon Corp now owns 1,194,110 shares of the medical research company’s stock valued at $119,196,000 after purchasing an additional 66,748 shares during the period. Finally, First Trust Advisors LP acquired a new stake in Iqvia in the second quarter valued at about $99,127,000. Institutional investors and hedge funds own 91.91% of the company’s stock.
In other Iqvia news, insider Ari Bousbib sold 368,640 shares of the stock in a transaction dated Thursday, July 26th. The shares were sold at an average price of $122.09, for a total value of $45,007,257.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John G. Danhakl sold 370,470 shares of the stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total transaction of $46,245,770.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 978,777 shares of company stock valued at $121,566,089. 6.00% of the stock is currently owned by corporate insiders.
Shares of Iqvia stock opened at $124.79 on Friday. Iqvia Holdings Inc has a 12-month low of $91.57 and a 12-month high of $132.24. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.13 and a quick ratio of 1.13. The stock has a market capitalization of $26.28 billion, a price-to-earnings ratio of 28.56, a P/E/G ratio of 1.86 and a beta of 0.70.
Iqvia (NYSE:IQV) last issued its earnings results on Tuesday, July 24th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.15. Iqvia had a net margin of 12.68% and a return on equity of 13.51%. The company had revenue of $2.57 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Iqvia’s revenue for the quarter was up 9.0% on a year-over-year basis. As a group, sell-side analysts predict that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.
A number of equities research analysts recently commented on IQV shares. Robert W. Baird raised their price objective on shares of Iqvia from $127.00 to $143.00 and gave the company an “outperform” rating in a research report on Wednesday, July 25th. Zacks Investment Research upgraded shares of Iqvia from a “hold” rating to a “buy” rating and set a $111.00 price objective for the company in a research report on Wednesday, July 4th. UBS Group started coverage on shares of Iqvia in a research report on Tuesday. They issued a “buy” rating for the company. Jefferies Financial Group restated a “hold” rating and issued a $119.00 price objective on shares of Iqvia in a research report on Friday, July 20th. Finally, ValuEngine upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a research report on Thursday, July 12th. Five equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $126.95.
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Featured Story: How to interpret a stock’s beta number
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.